1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
RESIDUE ALA 8 IS A D-ALANINE.
Fesik, S.W.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C4 H9 N O2
103.120
n
ALPHA-AMINOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C10 H19 N O3
201.263
n
4-METHYL-4-[(E)-2-BUTENYL]-4,N-METHYL-THREONINE
L-peptide linking
C3 H7 N O2
89.093
D-ALANINE
D-peptide linking
C7 H15 N O2
145.199
n
N-METHYLLEUCINE
L-peptide linking
C6 H13 N O2
131.173
n
N-METHYLVALINE
L-peptide linking
C3 H7 N O2
89.093
n
SARCOSINE
peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
30
6574
10.1021/BI00240A030
2054356
NMR Studies of [U-13C]Cyclosporin a Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding.
1991
US
J.Am.Chem.Soc.
JACSAT
0004
0002-7863
113
7080
10.1021/JA00018A080
Identification of Solvent-Exposed Regions of Enzyme-Bound Ligands by Nuclear Magnetic Resonance
1991
NE
FEBS Lett.
FEBLAL
0165
0014-5793
294
81
10.1016/0014-5793(91)81348-C
1H, 13C and 15N Backbone Assignments of Cyclophilin When Bound to Cyclosporin a (Csa) and Preliminary Structural Characterization of the Csa Binding Site
1991
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1220.625
CYCLOSPORIN A
1
syn
polymer
CYCLOSPORINE, CICLOSPORIN, CICLOSPORINE
no
yes
(DAL)(MLE)(MLE)(MVA)(BMT)(ABA)(SAR)(MLE)V(MLE)A
ALLVTAGLVLA
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
repository
Initial release
Version format compliance
Version format compliance
Atomic model
Database references
Derived calculations
Non-polymer description
Structure summary
Other
1
0
1994-01-31
1
1
2011-06-14
1
2
2011-07-13
1
3
2011-07-27
1
4
2012-12-12
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN C
CRYSTAL STRUCTURE OF THE CYCLOPHILIN-LIKE DOMAIN FROM BRUGIA MALAYI COMPLEXED WITH CYCLOSPORIN A
SOLUTION STRUCTURE OF E.COLI CYCLOPHILIN (F112W) COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 5
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN D
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A MODIFIED AT POSITION 7
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITION 7
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITIONS 5 AND 7.
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN D AT POSITIONS 5 AND 7.
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 8
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH NODIFIED CYCLOSPORIN C AT POSITIONS 1, AND 9
SOLUTION STRUCTURE OF HUMAN CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN B COMPLEXED WITH MODIFIED CYCLOSPORIN A
CRYSTAL STRUCTURE OF CTCLOSPORIN-FAB COMPLEX
CRYSTAL STRUCTURE OF CALCINEURIN-CYCLOPHILIN-CYCLOSPORIN COMPLEX
CRYSTAL STRUCTURE OF HUMAN CALCINEURIN COMPLEXED WITH HUMAN CYCLOPHILIN AND CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 6
CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF PLASMODIUM FALCIPARUM CYCLOPHILIN (DOUBLE MUTANT) COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF TRYPANOSOMA CRUZI CYCLOPHILIN COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN J COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM IOWA II CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN A COMPLEXED WITH MODIFIED CYCLOSPORIN A AT POSITION 5
CRYSTAL STRUCTURE OF MURINE CYCLOPHILIN C COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF THE PPIASE DOMAIN OF HUMAN CYCLOPHILIN G COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF HUMAN ACETYL-CYPA COMPLEXED WITH CYCLOSPORINE A
CRYSTAL STRUCTURE OF PPIL1 COMPLEXED WITH CYCLOSPORINE A
CRYSTAL STRUCTURE OF HUMAN CYCLOPHILIN D IN COMPLEX WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF CYCLOSPHILIN A FROM TOXOPLASMA GONDII COMPLEXED WIT CYCLOSPORIN A
SOLUTION STRUCTURE OF THE HUMAN CYCLOSPORIN A COMPLEXED WITH CYCLOSPORIN A
CRYSTAL STRUCTURE OF CYCLOPHILIN FROM LEISHMANIA DONOVANI COMPLEXED WITH CYCLOSPORIN A
Y
1992-02-24
REL
29910
TOLYPOCLADIUM INFLATUM
sample
CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
HERE, CYCLOSPORIN A IS REPRESENTED BY THE SEQUENCE (SEQRES)
Immunosuppressant
CYCLOSPORIN IS A CYCLIC UNDECAPEPTIDE.
CYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI.
Cyclosporin A
Cyclic peptide
20
HARE RESEARCH INC. (DSPACE), BRUNGER (X-PLOR)
refinement
DSPACE, X-PLOR
DAL
1
n
1
DAL
1
A
MLE
2
n
2
MLE
2
A
MLE
3
n
3
MLE
3
A
MVA
4
n
4
MVA
4
A
BMT
5
n
5
BMT
5
A
ABA
6
n
6
ABA
6
A
SAR
7
n
7
SAR
7
A
MLE
8
n
8
MLE
8
A
VAL
9
n
9
VAL
9
A
MLE
10
n
10
MLE
10
A
ALA
11
n
11
ALA
11
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
A
BMT
ABA
5
6
134.10
1
A
A
ABA
SAR
6
7
104.74
1
A
A
SAR
MLE
7
8
113.87
2
A
A
MLE
MVA
3
4
149.05
2
A
A
BMT
ABA
5
6
-131.98
2
A
A
ABA
SAR
6
7
-97.85
2
A
A
SAR
MLE
7
8
-141.91
3
A
A
DAL
MLE
1
2
145.90
3
A
A
MLE
MLE
2
3
-140.51
3
A
A
BMT
ABA
5
6
-98.20
3
A
A
ABA
SAR
6
7
-117.89
3
A
A
SAR
MLE
7
8
-105.22
4
A
A
DAL
MLE
1
2
142.81
4
A
A
MLE
MLE
2
3
-148.82
4
A
A
BMT
ABA
5
6
-148.29
4
A
A
ABA
SAR
6
7
-84.77
4
A
A
SAR
MLE
7
8
96.83
5
A
A
MLE
MLE
2
3
-148.86
5
A
A
MLE
MVA
3
4
141.02
5
A
A
BMT
ABA
5
6
-132.24
5
A
A
ABA
SAR
6
7
-117.97
5
A
A
SAR
MLE
7
8
-126.67
6
A
A
MLE
MLE
2
3
-147.56
6
A
A
MLE
MVA
3
4
149.11
6
A
A
BMT
ABA
5
6
-148.26
6
A
A
ABA
SAR
6
7
-110.90
6
A
A
SAR
MLE
7
8
-136.75
7
A
A
MLE
MLE
2
3
-148.96
7
A
A
MLE
MVA
3
4
149.87
7
A
A
BMT
ABA
5
6
-138.77
7
A
A
ABA
SAR
6
7
-132.52
7
A
A
SAR
MLE
7
8
-85.28
8
A
A
MLE
MLE
2
3
-147.29
8
A
A
BMT
ABA
5
6
-131.29
8
A
A
ABA
SAR
6
7
-144.35
9
A
A
MLE
MLE
2
3
-145.91
9
A
A
ABA
SAR
6
7
-118.33
9
A
A
SAR
MLE
7
8
78.80
10
A
A
BMT
ABA
5
6
111.38
10
A
A
SAR
MLE
7
8
-140.74
10
A
A
MLE
VAL
8
9
-144.50
11
A
A
DAL
MLE
1
2
139.22
11
A
A
MLE
MLE
2
3
-141.49
11
A
A
MLE
MVA
3
4
147.14
11
A
A
BMT
ABA
5
6
134.89
11
A
A
ABA
SAR
6
7
-145.38
11
A
A
SAR
MLE
7
8
-103.79
11
A
A
MLE
VAL
8
9
-143.41
12
A
A
DAL
MLE
1
2
137.33
12
A
A
MLE
MLE
2
3
-143.32
12
A
A
BMT
ABA
5
6
-130.66
12
A
A
ABA
SAR
6
7
-124.06
12
A
A
SAR
MLE
7
8
-78.16
12
A
A
MLE
VAL
8
9
-149.46
13
A
A
MLE
MLE
2
3
-146.56
13
A
A
BMT
ABA
5
6
145.64
13
A
A
ABA
SAR
6
7
-107.15
13
A
A
SAR
MLE
7
8
98.95
14
A
A
MLE
MLE
2
3
-146.56
14
A
A
ABA
SAR
6
7
-74.89
14
A
A
SAR
MLE
7
8
103.50
15
A
A
MLE
MLE
2
3
-143.80
15
A
A
ABA
SAR
6
7
-87.70
15
A
A
SAR
MLE
7
8
75.19
15
A
A
MLE
ALA
10
11
146.42
16
A
A
MLE
MVA
3
4
148.27
16
A
A
BMT
ABA
5
6
-133.38
16
A
A
ABA
SAR
6
7
-108.04
16
A
A
SAR
MLE
7
8
-133.39
17
A
A
SAR
MLE
7
8
50.34
18
A
A
MLE
MLE
2
3
-148.43
18
A
A
MLE
MVA
3
4
144.58
18
A
A
BMT
ABA
5
6
-120.54
18
A
A
ABA
SAR
6
7
-99.99
18
A
A
SAR
MLE
7
8
116.38
18
A
A
MLE
ALA
10
11
147.15
19
A
A
MLE
MLE
2
3
-148.51
19
A
A
ABA
SAR
6
7
-103.05
19
A
A
SAR
MLE
7
8
84.61
20
A
A
MLE
MLE
2
3
-140.54
20
A
A
BMT
ABA
5
6
-127.79
20
A
A
ABA
SAR
6
7
-127.32
20
A
A
SAR
MLE
7
8
-89.71
20
A
A
MLE
ALA
10
11
122.21
2
A
BMT
5
-117.43
-169.44
2
A
ABA
6
-164.69
46.02
3
A
BMT
5
-123.07
-167.58
3
A
ABA
6
-141.35
47.35
4
A
MLE
3
-65.26
-178.54
4
A
ABA
6
-155.75
65.36
5
A
MLE
3
-66.45
-175.50
5
A
BMT
5
-126.61
-167.30
5
A
ABA
6
-154.15
57.27
6
A
ABA
6
-100.74
76.07
7
A
BMT
5
-116.33
-163.99
7
A
ABA
6
-150.84
72.50
8
A
ABA
6
-142.60
49.98
9
A
MLE
2
-107.74
47.01
10
A
ABA
6
35.17
40.52
11
A
MLE
3
-67.29
-177.41
12
A
MLE
3
-68.93
-172.97
12
A
ABA
6
-113.78
59.27
13
A
MLE
2
-108.20
53.85
13
A
MLE
10
-105.60
-168.49
14
A
MLE
10
-101.01
-169.27
16
A
MLE
2
-112.59
60.43
17
A
ABA
6
55.00
175.38
17
A
MLE
8
-115.26
72.86
18
A
MLE
2
-109.66
49.01
18
A
BMT
5
-131.39
-155.78
18
A
ABA
6
-174.71
36.23
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
CYCLOSPORIN A
NMR STUDIES OF (U-13C)CYCLOSPORIN A BOUND TO CYCLOPHILIN: BOUND CONFORMATION AND PORTIONS OF CYCLOSPORIN INVOLVED IN BINDING
1
N
N
covale
1.307
A
DAL
1
A
N
DAL
1
1_555
A
ALA
11
A
C
ALA
11
1_555
covale
1.319
A
DAL
1
A
C
DAL
1
1_555
A
MLE
2
A
N
MLE
2
1_555
covale
1.310
A
MLE
2
A
C
MLE
2
1_555
A
MLE
3
A
N
MLE
3
1_555
covale
1.311
A
MLE
3
A
C
MLE
3
1_555
A
MVA
4
A
N
MVA
4
1_555
covale
1.321
A
MVA
4
A
C
MVA
4
1_555
A
BMT
5
A
N
BMT
5
1_555
covale
1.307
A
BMT
5
A
C
BMT
5
1_555
A
ABA
6
A
N
ABA
6
1_555
covale
1.312
A
ABA
6
A
C
ABA
6
1_555
A
SAR
7
A
N
SAR
7
1_555
covale
1.314
A
SAR
7
A
C
SAR
7
1_555
A
MLE
8
A
N
MLE
8
1_555
covale
1.310
A
MLE
8
A
C
MLE
8
1_555
A
VAL
9
A
N
VAL
9
1_555
covale
1.317
A
VAL
9
A
C
VAL
9
1_555
A
MLE
10
A
N
MLE
10
1_555
covale
1.305
A
MLE
10
A
C
MLE
10
1_555
A
ALA
11
A
N
ALA
11
1_555
IMMUNOSUPPRESSANT
IMMUNOSUPPRESSANT, CYCLOSPORIN A
NOR00033
NOR
1
NOR00033
1
11
1CYB
1
11
NOR00033
A
1
1
11
1
P 1